Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies. 2011

Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
Division of Anti-aging, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa 359-8513, Japan.

OBJECTIVE Pioglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, reportedly reduces cardiovascular events in diabetic patients. ATP cassette binding transporters (ABC) A1 and G1 are pivotal molecules for cholesterol efflux (ChE) from macrophages and high density-lipoprotein biogenesis, and the A1 transporter is regulated by a PPARγ-liver receptor X (LXR) pathway. Also, pioglitazone induces ABCG1 expression, though the exact mechanism remains unclear. We therefore investigated the effects of pioglitazone on ABCA1/G1 expression in vitro and ex vivo. METHODS The effects of pioglitazone on ChE and ABCA1/G1 expressions in macrophages were assessed. Then, mRNA was quantified in macrophages when PPARγ/LXR inhibition by siRNA or overexpression of oxysterol sulfotransferase was performed. ABCA1/G1 promoter activity with mutated LXR-responsive elements was also measured. As an ex vivo study, 15 type 2 diabetic patients were administered pioglitazone or placebo, and ChE assays and protein expressions were determined using macrophages cultured with the corresponding sera. RESULTS Pioglitazone increased LXRα/ABCA1/G1 expressions, which enhanced ChE from macrophages. Inhibition of PPARγ/LXR pathways revealed that LXR was primarily involved in pioglitazone's transactivation of ABCA1 but only partially involved for ABCG1. Promoter assays showed that ABCG1 was regulated more by the promoter in intron 4 than that upstream of exon 1 but both promoters were responsive to LXR activation. Sera obtained after pioglitazone treatment promoted ChE and ABCA1/G1 expressions in macrophages. CONCLUSIONS Pioglitazone enhanced ChE from macrophages by increasing ABCA1/G1 in LXR-dependent and -independent manners. Our comparable in vitro and ex vivo results shed new light on pioglitazone's novel anti-atherogenic property.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070998 ATP Binding Cassette Transporter, Subfamily G, Member 1 ATP binding cassette transporter that functions primarily as a lipid and CHOLESTEROL exporter in MACROPHAGES. It may also function in intracellular lipid transport and homoeostasis. ABCG1 Protein,ABCG1 Transporter,ATP Binding Cassette Transporter, Sub-Family G, Member 1,ATP-Binding Cassette Transporter 8,White Protein Homolog,ATP Binding Cassette Transporter 8
D000071518 Liver X Receptors Nuclear receptors that bind OXYSTEROLS and function as heterodimers with RETINOID X RECEPTORS. They have important functions in regulating cholesterol homeostasis, ENERGY METABOLISM; INFLAMMATION; and the immune response. LXR-Alpha Protein,LXRalpha Protein,LXRbeta Protein,Liver X Receptor,Liver X Receptor Alpha,Liver X Receptor Beta,Liver X Receptor-Alpha,Liver X Receptor-Beta,NR1H2 Protein,NR1H3 Protein,Nuclear Orphan Receptor LXR-Alpha,Nuclear Oxysterol Receptors,Nuclear Receptor Subfamily 1, Group H, Member 2,Nuclear Receptor Subfamily 1, Group H, Member 3,Oxysterols Receptor LXR-Alpha,Oxysterols Receptor LXR-Beta,LXR Alpha Protein,LXR-Alpha, Oxysterols Receptor,LXR-Beta, Oxysterols Receptor,Nuclear Orphan Receptor LXR Alpha,Oxysterol Receptors, Nuclear,Oxysterols Receptor LXR Alpha,Oxysterols Receptor LXR Beta
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A
D045162 Thiazolidinediones THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). Glitazones

Related Publications

Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
October 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
December 2018, Life sciences,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
December 2022, Biochimica et biophysica acta. Molecular and cell biology of lipids,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
May 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
June 2016, FEBS letters,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
July 2019, Biochemical and biophysical research communications,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
August 2020, Archives of pharmacal research,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
June 2014, Biochemical and biophysical research communications,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
July 2021, Pharmacological research,
Hideki Ozasa, and Makoto Ayaori, and Maki Iizuka, and Yoshio Terao, and Harumi Uto-Kondo, and Emi Yakushiji, and Shunichi Takiguchi, and Kazuhiro Nakaya, and Tetsuya Hisada, and Yoshinari Uehara, and Masatsune Ogura, and Makoto Sasaki, and Tomohiro Komatsu, and Shunpei Horii, and Seibu Mochizuki, and Michihiro Yoshimura, and Katsunori Ikewaki
January 2018, Theranostics,
Copied contents to your clipboard!